CD33 and acute myeloid leukemia: Therapies targeting the AML cell surface antigen CD33 include the approved antibody drug conjugate gemtuzumab ozogamycin (My96) and investigational CART approaches incorporating CD33-binding domains derived from humanized scFvs.